FDA Approved: EMPLICITI — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

The FDA approved a supplemental application for EMPLICITI (elotuzumab) from E.R. Squibb & Sons, L.L.C., resulting in a labeling/indication update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Empliciti (elotuzumab)

Snippet

SUPPL AP for EMPLICITI (ELOTUZUMAB)